Increased Mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists

Journal of Epidemiology

Volumn 19, Issue 1, 2009, Pages 17-23

  Yang, Hsiao Yu ^a,b   Wang, Jung Der ^a,c   Lo, Tsai Chang ^d   Chen, Pau Chung ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Public Health Bureau   (Taiwan)

Author keywords

Aristolochic acid; Chinese herbal drugs; Chinese herbalist; Chronic kidney disease; Urological cancer

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; CARCINOGEN; PLANT EXTRACT;

ADOLESCENT; ADULT; ARTICLE; ASIAN; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HEALTH SURVEY; HUMAN; KIDNEY DISEASE; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; OCCUPATIONAL DISEASE; PHYTOTHERAPY; RISK; STATISTICS; TAIWAN; URINARY TRACT CANCER;

ADOLESCENT; ADULT; ARISTOLOCHIC ACIDS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOGENS; COHORT STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; KIDNEY DISEASES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; PHYTOTHERAPY; PLANT EXTRACTS; RISK; TAIWAN; UROLOGIC NEOPLASMS;

EID: 60549116138     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20080035     Document Type: Article

References (50)

1. Chen FP, Chen TJ, Kung YY, Chen YC, Chou LF, Chen FJ, et al. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res 2007;7:26.
2. Chung V, Wong E, Woo J, Lo SV, Griffiths S. Use of traditional Chinese medicine in the Hong Kong special administrative region of China. J Altern Complement Med 2007;13:361-7.
3. Normile D. The new face of traditional Chinese medicine. Science 2003;299:188-90.
4. Lee CH, Chen JJ, Liang WM. Attitudes and intentions of patients toward integrated Chinese and Western medicine in Taiwan. J Altern Complement Med 2006;12:233-6.
5. Liu CT. Health care systems in transition. II. Taiwan, Part I. A general overview of the health care system in Taiwan. J Public Health Med 1998;20:5-10.
6. Chi C, Lee JL, Lai JS, Chen CY, Chang SK, Chen SC. The practice of Chinese medicine in Taiwan. Soc Sci Med 1996;43:1329-48.
7. Chang CH, Wang YM, Yang AH, Chiang SS. Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. Am J Nephrol 2001;21:441-8.
8. Yang SS, Chu P, Lin YF, Chen A, Lin SH. Aristolochic acidinduced Fanconi's syndrome and nephropathy presenting as hypokalemic paralysis. Am J Kidney Dis 2002;39:E14.
9. Yang HY, Lin JL, Chen KH, Yu CC, Hsu PY, Lin CL. Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. J Nephrol 2006;19:111-4.
10. Vanherweghem JL. Nephropathy and herbal medicine. Am J Kidney Dis 2000;35:330-2.
11. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 2000;35:313-8.
12. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis 2004;44:1-11.
13. National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System, USRDS 2006 Annual Data Report: International comparisons. Available at: http://www.usrds.org/. Accessed March 11, 2008.
14. Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis 2006;48:727-38.
15. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 2007;49:626-33.
16. Chan K. Progress in traditional Chinese medicine. Trends Pharmacol Sci 1995;16:182-7.
17. Cheng JT. Review: drug therapy in Chinese traditional medicine. J Clin Pharmacol 2000;40:445-50.
18. Unschuld PU, editor. Huang Di Nei Jing Su Wen: Nature, Knowledge and Imagery in an Ancient Chinese Medical Text. London: University of California Press. Ltd; 2003.
19. Chang HC, Tsai KH. Characteristics of Chinese herbalists in Taiwan. Disquisitions on the Past and Present 2004;11:96-114 (in Chinese).
20. Hsieh GY, Chen PC, Wang JD. Verification and correction of error for death registration data of the department of health R.O.C. between 1980 and 1997. Taiwan J Public Health 2002;21:329-38 (in Chinese).
21. National Institute for Occupational Safety and Health. Life Table Analysis System. Available at: http://www.cdc.gov/niosh/LTAS/default.html. Accessed March 11, 2008.
22. Lo TC. A case-control study of chronic renal disease on herbalists in Taiwan [Dissertation]. Taipei, Taiwan: National Taiwan University, College of Public Health, 2003. (in Chinese).
23. Liang WM, Kuo HW, Wang CB. Prevalence of Tobacco Smoking, Drinking, and Betel Nut Chewing Among Taiwanese Workers in 1999. Mid-Taiwan J Med 2002;7:146-54.
24. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000;89:630-9.
25. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999;81:542-8.
26. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001;153:411-8.
27. Chen CJ, Hsu LI,Wang CH, Shih WL, Hsu YH, Tseng MP, et al. Biomarkers of exposure, effect, and susceptibility of arsenicinduced health hazards in Taiwan. Toxicol Appl Pharmacol 2005;206:198-206.
28. Zhang C, Wang X, Shang M, Yu J, Xu Y, Li Z, et al. Simultaneous determination of five aristolochic acids and two aristololactams in Aristolochia plants by high-performance liquid chromatography. Biomed Chromatogr 2006;20:309-18.
29. Wu KM, Farrelly JG, Upton R, Chen J. Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochiarelated species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 2007;14:273-9.
30. Jong TT, Lee MR, Hsiao SS, Hsai JL, Wu TS, Chiang ST, et al. Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry. J Pharm Biomed Anal 2003;33:831-7.
31. Drew AK, Whyte IM, Bensoussan A, Dawson AH, Zhu X, Myers SP. Chinese herbal medicine toxicology database: monograph on Herba Asari, " xi xin" . J Toxicol Clin Toxicol 2002;40:169-72.
32. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-91.
33. Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999;33:1011-7.
34. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-92.
35. International Agency for Research on Cancer. Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. Available at: http://monographs.iarc.fr/ENG/Monographs/vol82/volume82.pdf. Accessed May 25, 2008.
36. Arlt VM, Stiborová M, vom Brocke J, Simões ML, Lord GM, Nortier JL, et al. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 2007;28:2253-61.
37. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 2007;104:12129-34.
38. Koh HL, Woo SO. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf 2000;23:351-62.
39. Wu TN, Yang KC, Wang CM, Lai JS, Ko KN, Chang PY, et al. Lead poisoning caused by contaminated Cordyceps, a Chinese herbal medicine: two case reports. Sci Total Environ 1996;182:193-5.
40. Au AM, Ko R, Boo FO, Hsu R, Perez G, Yang Z. Screening methods for drugs and heavy metals in Chinese patent medicines. Bull Environ Contam Toxicol 2000;65:112-9.
41. Ernst E, Thompson Coon J. Heavy metals in traditional Chinese medicines: a systematic review. Clin Pharmacol Ther 2001;70:497-504.
42. Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz Martinez MC, et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis 2008;51:471-7.
43. Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 2008;15:53-5.
44. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, et al. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J 2005;46:116-25.
45. Grollman AP, Jelakovic B. Role of environmental toxins in endemic (Balkan) nephropathy. J Am Soc Nephrol 2007;18:2817-23.
46. Chernozemsky IN, Stoyanov IS, Petkova-Bocharova TK, Nicolov IG, Draganov IV, Stoichev II, et al. Geographic correlation between the occurrence of endemic nephropathy and urinary tract tumours in vratza district, Bulgaria. Int J Cancer 1977;19:1-11.
47. Dragicevic D, Djokic M, Pekmezovic T, Micic S, Hadzi-Djokic J, Vuksanovic A, et al. Survival of patients with transitional cell carcinoma of the ureter and renal pelvis in Balkan endemic nephropathy and non-endemic areas of Serbia. BJU Int 2007;99:1357-62.
48. Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere 2003;52:1361-71.
49. Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997;37:344-50.
50. Ernst E. Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 2004;13:767-71.